



12 January 2016

To: Recipients of M100S, 26th ed.

From: Jennifer K. Adams, MT(ASCP), MSHA

Subject: Errors in Tables 2D and 2H-2 for Antimicrobial Agent Telavancin in
CLSI Document M100S

This notification is to inform you of errors in Tables 2D and 2H-2 for antimicrobial agent telavancin in CLSI document M100S, 26th ed., *Performance Standards for Antimicrobial Susceptibility Testing*.

The susceptible minimal inhibitory concentration (MIC) interpretive criteria for telavancin in Tables 2D and 2H-2 is incorrect and has been corrected as shown highlighted below:

Table 2D. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Enterococcus* spp.

Test/Report Group	Antimicrobial Agent	Disk Content	Zone Diameter Interpretive Criteria (nearest whole mm)			MIC Interpretive Criteria (µg/mL)			Comments
			S	I	R	S	I	R	
LIPOGLYCOPEPTIDES									
C	Oritavancin	–	–	–	–	≤0.12	–	–	(10) For reporting against vancomycin-susceptible <i>E. faecalis</i> .
C	Telavancin	30 µg	≥15	–	–	≤0.25	–	–	See comment (10).

Abbreviations: I, intermediate; MIC, minimal inhibitory concentration; R, resistant; S, susceptible.

Table 2H-2. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Streptococcus* spp. Viridans Group

Test/Report Group	Antimicrobial Agent	Disk Content	Zone Diameter Interpretive Criteria (nearest whole mm)			MIC Interpretive Criteria (µg/mL)			Comments
			S	I	R	S	I	R	
LIPOGLYCOPEPTIDES									
C	Oritavancin	–	–	–	–	≤0.25	–	–	
C	Telavancin	30 µg	≥15	–	–	≤0.06	–	–	

Abbreviations: I, intermediate; MIC, minimal inhibitory concentration; R, resistant; S, susceptible.

If you require any additional clarification regarding this correction, please contact CLSI Customer Service (customerservice@clsi.org).

We appreciate your commitment to CLSI, and regret any inconvenience.